8-K: Abbott Labs Reports Q2 2026 Results, Raises EPS Guidance

Abbott Laboratories announced strong second-quarter 2026 financial results, with reported sales up 13.0% and comparable sales up 4.8%, while raising its full-year adjusted diluted EPS guidance.

Summary

• Abbott Laboratories reported second-quarter 2026 results with total reported sales increasing by 13.0% to $12.593 billion, and comparable sales growth of 4.8%.
• GAAP diluted earnings per share (EPS) was $0.53, while adjusted diluted EPS was $1.31.
• The company reaffirmed its full-year 2026 comparable sales growth guidance of 6.5% to 7.5%.
• Full-year 2026 adjusted diluted EPS guidance was raised to a range of $5.45 to $5.60, up from the previous $5.38 to $5.58.
• Abbott returned $2.1 billion to shareholders in the second quarter through dividends and share repurchases.
• Key business segments showed varied performance: Diagnostics sales grew 42.3% reported and 2.9% comparable, driven by Exact Sciences acquisition and Cologuard performance.
• Medical Devices sales increased 9.0% reported and 8.4% comparable, with strong contributions from Electrophysiology and Diabetes Care.
• Established Pharmaceuticals saw an 8.4% reported and 8.7% comparable sales increase, particularly in Key Emerging Markets.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, with strong sales growth and an increase in full-year EPS guidance, despite some segment-specific headwinds and increased interest expenses.

Positives

• Reported sales growth of 13.0% and comparable sales growth of 4.8% in the second quarter.
• Raised full-year 2026 adjusted diluted EPS guidance to $5.45 $5.60.
• Reaffirmed full-year 2026 comparable sales growth guidance of 6.5% 7.5%.
• Strong performance in the Diagnostics segment, with comparable sales growth of 2.9%, boosted by the Exact Sciences acquisition and mid-teens growth in Cologuard.
• Medical Devices segment delivered robust comparable sales growth of 8.4%, led by Electrophysiology (13.4%) and Diabetes Care (9.0%).
• Established Pharmaceuticals segment achieved comparable sales growth of 8.7%, with double-digit growth in Latin America and Asia Pacific.
• Returned $2.1 billion to shareholders via dividends and share repurchases.
• CE Mark secured for Libre Duo, a dual glucose-ketone biowearable sensor.

Negatives

• Worldwide Nutrition sales decreased 3.1% on a reported basis and 3.6% on a comparable basis, attributed to lower sales volumes and strategic pricing actions.
• GAAP diluted EPS decreased by 47.8% to $0.53 compared to $1.01 in the prior year, largely due to specified items.
• Operating earnings decreased by 17.5% to $1.693 billion.
• Interest expense, net increased significantly to $299 million from $50 million in the prior year.

Risks

• Economic, competitive, governmental, and technological factors may affect Abbott's operations.
• Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.
• Potential for legal reserves related to an agreed-in-principle settlement.
• Incremental costs to comply with European Union's Medical Device Regulations (MDR) and In Vitro Diagnostics Medical Device Regulations (IVDR).

Future Outlook

Abbott projects full-year 2026 comparable sales growth of 6.5% to 7.5% and has raised its full-year 2026 adjusted diluted EPS guidance to $5.45 to $5.60. The company anticipates this momentum will continue, driving accelerating sales and earnings growth in the second half of the year. Third-quarter 2026 adjusted diluted EPS is projected to be between $1.38 and $1.46.

Management Comments

• "Our second-quarter results reflect the momentum we are building. We expect this momentum to continue and drive accelerating sales and earnings growth in the second half of the year."
• Management believes that measuring sales growth on a comparable basis is an appropriate way for investors to best understand the underlying performance of the business.
• Abbott's management believes the presentation of non-GAAP financial measures provides useful information to investors regarding results of operations as these measures allow investors to better evaluate ongoing business performance.

Industry Context

StockSavvy.ai notes that Abbott's performance in Diagnostics, particularly with the Exact Sciences acquisition and Cologuard, aligns with the broader industry trend of increased focus on early cancer detection and personalized medicine. The growth in Medical Devices, especially in Electrophysiology and Diabetes Care, reflects ongoing innovation and demand for advanced healthcare solutions.

Comparison to Industry Standards

• Abbott's comparable sales growth of 4.8% in Q2 2026 is a solid performance within the diversified healthcare sector, which has seen varied growth rates across segments.
• The Diagnostics segment's 2.9% comparable growth, despite a high reported growth due to acquisition, is competitive, especially considering the comparison base for respiratory virus tests.
• Medical Devices' 8.4% comparable growth is strong, outperforming many peers in areas like Electrophysiology and Diabetes Care, where innovation drives market share.
• Established Pharmaceuticals' 8.7% comparable growth in emerging markets is a key differentiator, showcasing Abbott's strength in high-growth regions compared to many Western-centric pharmaceutical companies.

Legal Proceedings

• Legal reserves related to an agreed-in-principle settlement, subject to satisfaction of certain contingencies.

Stakeholder Impact

• Shareholders: Benefit from increased EPS guidance and continued dividend payments, with $2.1 billion returned in Q2.
• Employees: Potential impact from restructuring and cost reduction initiatives, though not detailed in this report.
• Customers: Benefit from new product innovations like Libre Duo and advancements in medical devices and diagnostics.
• Suppliers: Continued demand for products across Abbott's diverse business segments.

Next Steps

• Continue to monitor the integration of Exact Sciences and its impact on the Diagnostics segment.
• Evaluate the performance of new product launches, such as Libre Duo and the TECTONIC IVL System.
• Observe the impact of strategic pricing actions in the Nutrition segment.
• Monitor the resolution of legal reserves and compliance with MDR/IVDR regulations.

Key Dates

Recommendation

The company demonstrated solid execution with raised guidance and strong performance in key segments like Medical Devices and Diagnostics. However, the decline in Nutrition sales, increased interest expenses, and the significant GAAP EPS decrease warrant a cautious 'hold' rating until the Nutrition segment's performance stabilizes and the impact of specified items on GAAP earnings is better understood.

Keywords

Abbott Laboratories, Q2 2026 Earnings, Medical Devices, Diagnostics, Nutrition, Pharmaceuticals, EPS Guidance, Sales Growth